The topical treatment of psoriasis

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 2, 2003, Pages 69-83

  Van De Kerkhof, P C M ^a   Vissers, W H P M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Corticosteroids; Dithranol; Psoriasis; Retinoids; Salicylic acid; Tar; Vitamin D3 analogues

Indexed keywords

ASCORBIC ACID; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CETOSTEARYLIC ALCOHOL; CLOBETASOL PROPIONATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; DIFLORASONE; DITHRANOL; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE ACETATE; MOMETASONE FUROATE; OLEIC ACID; RETINOID; SALICYLIC ACID; SORBIC ACID; SORBITOL; TACALCITOL; TAR; TAZAROTENE; TRIAMCINOLONE ACETONIDE;

ACNE; ARTICLE; CLINICAL TRIAL; CONTACT ALLERGY; CREAM; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ECCHYMOSIS; HAIR DISEASE; HUMAN; HYPERTRICHOSIS; HYPOPIGMENTATION; INTOXICATION; MONOTHERAPY; PATIENT COMPLIANCE; PERIORAL DERMATITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SKIN ATROPHY; SKIN INFECTION; SKIN IRRITATION; STRIA; TELANGIECTASIA; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, TOPICAL; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; CHOLECALCIFEROL; COAL TAR; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PATIENT COMPLIANCE; PSORIASIS; RETINOIDS; SALICYLIC ACID;

EID: 0037233046     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069029     Document Type: Article

References (65)

1. van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-298.
2. van de Kerkhof PCM: Dithranol after 75 years still going strong. Eur J Dermatol 1991;1:77-80.
3. Kemeny L, Ruzicka T, Braun-Falco O: Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990;3:1-20.
4. Swinkels OQJ, Prins M, Gerritsen MJP, van Vlijmen-Willems, van der Valk PGM, van de Kerkhof PCM: An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated application of high dose dithranol cream. Skin Pharmacol Appl Skin Physiol, in press.
5. Prins M, Swinkels OQJ, Bouhuis S, de Gast MJ, Boer PCM: Dithranol in a cream: Disperse or dissolved? Skin Pharmacol Appl Skin Physiol 2000;13:273-279.
6. Schaefer H, Farber EM, Goldberg L, Schalla W: Limited application period for dithranol in psoriasis: Preliminary report on penetration and clinical efficacy. Br J Dermatol 1980;102:571-573.
7. Berth Jones J, Chu AC, Dodd WA: A multicentre parallel group comparison of calcipotriol ointment and short contact dithranol treatment in chronic plaque psoriasis. Br J Dermatol 1992;127:266-271.
8. Swinkels OQJ, Prins M, de Boo T, Severens JL, van der Wilt GJ, van Zon AAJC: Report: Evaluation of a care instruction programme for psoriasis in day-care treatment (in Dutch). Rapport ontwikkelingsgeneeskunde. Evaluatieonderzoek. Gecombineerde dag-en thuisbehandeling van psoriasis. Eindredactie: van der Valk PGM. Nijmegen, Dermatologie, UMC St Radboud, 2000, pp 1-63.
9. Hartman M, Prins M, Swinkels OQJ, Severens JL, de Boo T, van der Wilt GJ, van de Kerkhof PCM, van der Valk PGM: Cost effectiveness analysis of psoriasis care instruction programme with dithranol compared to UVB phototherapy and in patient dithranol treatment. Br J Dermatol, in press.
10. Prins M, Swinkels OQJ, van de Kerkhof PCM, van der Valk PGM: The impact of the frequency of short contact dithranol treatment: Twice daily applications or three weekly applications of dithranol. Eur J Dermatol 2001;11:214-218.
11. Prins M, Swinkels OQJ, Bertholet B, van der Valk PGM: Dithranol short contact treatment of scalp psoriasis. J Dermatol Treat 1999;10:13-17.
12. Swinkels OQJ, Prins M, Kucharekova M, de Boo Th, Gerritsen MJP, van der Valk PGM, van de Kerkhof PCM: Combining lesional short contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol, in press.
13. 3 receptor in the context of the nuclear receptor superfamily. Endocrine J 1996;4:95-105.
14. Ashcroft DM, Po AL, Williams HC, Griffiths CE: Systemic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-967.
15. Berth Jones J: Calcipotriol in dermatology. Br J Clin Pract 1996;suppl 83:1-30.
16. Thaci D, Daiber W, Boehncke WH, Kaufmann R: Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153-156.
17. Kienbaum S, Lehmann P, Ruzicka T: Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996;135:647-650.
18. Amon U: Clinical experience with topical calcitriol 3μg/g. Presented at satellite symposium 6 during 10th congress of EADV in Munich. J Eur Acad Dermatol Venereol 2001;15(suppl 2):96.
19. Van de Kerkhof PCM, Werfel T, Haustein, Luger T, Czarnetzki BM, Nieman R, Planitz-Steuzel K: Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicenter, placebo-controlled, double blind study on efficacy and safety. Br J Dermatol 1996;135:758-765.
20. Van de Kerkhof PCM, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM: Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002;204:214-221.
21. Darby CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N: Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996;135:390-391.
22. Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, Rosenthal D, De Waard-van der Spek FB, Molin L, Axelsen M: Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997;36:203-208.
23. Bourke JF, Featherstone S, Iqbal SJ, Hutchinson PE: A double blind comparison of topical calcitriol (3 μg/g) and calcipotriol (50 μg/g) in the treatment of chronic plaque psoriasis vulgaris (abstract). Br J Dermatol 1995;133(suppl 45):17.
24. Hutchinson PE, Marks R, White J: The efficacy, safety and tolerance of calcitriol 3 μg/g ointment in the treatment of plaque psoriasis: A comparison with short contact dithranol. Dermatology 2000;201:139-145.
25. Veien NK, BjerkeJR, Rossmann-Ringdahl I, Jakobsen HB: Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol: A double blind trial. Br J Dermatol 1997;137:581-586.
26. van de Kerkhof PCM: Rotational and combination treatment. Clin Exp Dermatol 2001;26:535-561.
27. Bourke JF, Berth Jones J, Hutchinson PE: Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-506.
28. Nielsen PG: Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for a treatment of nummular psoriasis. Acta Derm Venereol 1993;73:394.
29. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J: A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-269.
30. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Møller K, Ruzicka T, van de Kerkhof PCM: Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: Tolerability and efficacy. Br J Dermatol 1998;139:649-654.
31. Ruzicka T, Lorenz B: Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks treatment with calcipotriol in the topical therapy of psoriasis vulgaris: A multicenter, double blind, randomized study. Br J Dermatol 1998;138:254-258.
32. Papp KA, Talbot DJ: Rapid onset of action and superior efficacy in psoriasis vulgaris with a new combination product containing calcipotriol and betamethasone dipropionate in a new vehicle (abstract). J Eur Acad Dermatol Venereol 2001;15(suppl 2):245.
33. Guenther L, Springborg: A new combination of calcipotriol and bethamethasone dipropionate is effective used once daily in psoriasis vulgaris (abstract). J Eur Acad Dermatol Venereol 2001;15(suppl 2):237.
34. Van Rossum MM, van Erp PEJ, van de Kerkhof PCM: Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: A flow cytometry study. Dermatology 2001;203:148-152.
35. Ring J, Kowalzik L, Christophers E, Schill WB, Schöpf E, Ständer M, Wolff HH, Altmeyer P: Calcitriol 3 μg/g ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: Results of a comparative study. Br J Dermatol 2001;144:495-499.
36. Ramsay CA, Berth Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PCM, Menné T, Wegmann E: Long-term use of topical calcipotriol in chronic plaque type psoriasis. Dermatology 1994;189:260-264.
37. Cullen I: Long term effectiveness and safety of topical calcipotriene for psoriasis. South Med J 1996;89:1053-1056.
38. Gerritsen MJP, van de Kerkhof PCM, Langer A: Long term safety of topical calcitriol 3 μg/g ointment. Br J Dermatol 2001;144(suppl 58):17-19.
39. Van de Kerkhof PCM, Berth Jones J, Griffiths CED, Harrison PV, Hönigsmann H, Marks R, Roelandts R, Schöpf E, Trompke C: A multicentre open prospective study to investigate the longterm safety and efficacy of tacalcitol in non-hospitalized patients with psoriasis. Br J Dermatol 2002;146:414-422.
40. Lebwohl M, Yoles A, Lombardi K, Lou W: Calcipotriene ointment and halobethasol ointment in the long term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998;39:447-450.
41. 3 for the treatment of plaque psoriasis: A pilot study. Br J Dermatol 2001;144:500-506.
42. Pariser DM, Pariser RJ, Breneman D, Lebwohl M, Kabb R, Moore J, Moss H, Parker C, Fiedler V: Calcipotriene ointment applied once a day for psoriasis: A double blind, multicenter, placebo controlled study. Arch Dermatol 1996;132:1527.
43. Hington A, Quell J: Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. J Am Acad Dermatol 1995;32:67-72.
44. Van de Kerkhof PCM, Franssen M, de La Brassine M, Kuipers M: Calcipotriol cream in the morning and ointment in the evening: A novel regimen to improve compliance. J Dermatol Treat 2001;12:75-79.
45. Sulzberger MB, Witten VH: The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19:101-102.
46. Hughes J, Rustin MHA: Corticosteroids; in van de Kerkhof PCM (ed): Textbook of Psoriasis. Oxford, Blackwell Science, 1999, pp 148-59.
47. Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM: Betamethasone in optimized vehicle: Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987;123:1308-1311.
48. Lagos BR, Maibach AI: Frequency of application of topical corticosteroids: An overview. Br J Dermatol 1998;139:763-766.
49. Degreef H, Dooms-Goossens A: The new corticosteroids: Are they effective and safe? Dermatol Clin 1993;11:155-160.
50. Medansky RS, Bressink R, Cole GW: Momethasone furoate ointment and cream 0.1% in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025% and triamcinolone 0.1%. Cutis 1988;42:480-485.
51. Rosenthal D, Duke E: A clinical investigation of the efficacy and safety of mometasone fuorate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res 1988;44:790-800.
52. Callen J: Comparison of safety and efficacy of fluticasone propionate cream 0.05% and betamethasone valerate cream 0.1% in the treatment of moderate to severe psoriasis. Cutis 1996;57:45-50.
53. Volden G, Kragballe K, van de Kerkhof P, Ahberg A, White R: Remission and relapse of chronic plaque psoriasis, treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatol Treat 2002;12:141-144.
54. Frost P, Weinstein JD: Topical administration of vitamin A acid from ichthyosiform dermatoses and psoriasis. JAMA 1969;207:1863-1868.
55. Krueger GG, Drake LA, Elias PM, Lowen NJ, Guzzo C, Weinstein GD, Lewkaya DA, Lue JC, Jefton J, Chandraratna RAS: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60.
56. Marks R: Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol 1997;37:S25-S32.
57. Lebwohl M, Ast E, Callen JP, Gullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Philips TJ, Rosen T, Wolf DI, Quell JM, Jefton J, Lue JC, Gibson JR, Chandraratna RAS: Once daily tazarotene gel versus twice daily flucinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-711.
58. Lebwohl M: Strategies to optimise efficacy, duration of remission and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000;42(suppl):43-46.
59. Kaidberg K, Kopper SC, Seflon J: A pilot study to determine the effect of tazarotene 0.1% gel on steroid induced epidermal atrophy. Poster Am Acad Dermatol, New Orleans, 2000.
60. Koo JYM, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Setton J, Gibson JR: Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000;43:821-828.
61. Behrens S, Grundmann-Kollmann M, Schnieder R: Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor selective topical retinoid. Br J Dermatol 1999;141:177.
62. Gollnick H, Bonnekoh B: Retinoide in der topischen Anwendung: Tazaroten; in Gollnick H, Bonnekoh B (eds): Psoriasis - Pathogenesis, Klinik und Therapie. Bremen, UniMed Science, 2001, pp 200-202.
63. Bershad S, Singer GK, Parente JE, Tan MH, Sherer DW, Persaud AN, Lebwohl M: Successful treatment of acne vulgaris using a new method. Arch Dermatol 2002;138:481-489.
64. Danielsen AG, Heidenheim M, Wulf HC: Crude coal tar treatment every day versus every other day for plaque psoriasis. Acta Derm Venereol 2001;81:221-222.
65. Van de Kerkhof PCM, de Hoop D, De Kort J, Kuipers MV: Scalp psoriasis: Clinical presentations and therapeutic management. Dermatology 1998;197:326-334.